AUSTRALIAN pharmaceutical
company QRxPharma has vowed to
fight the US Food and Drug
Administration’s decision not to
approve Moxduo.
The painkiller contains both
oxycodone and morphine and
QRxPharma had hoped to have the
drug approved and on the US
market by September this year.
Last week’s refusal saw almost
two thirds of the company’s share
value wiped off the market,
however the company is positive
that it can deal with the FDA’s
concerns in a scheduled meeting
now set for August.
Speaking to media QRx’s John
Holaday said “I’m confident about
overcoming this”.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jul 12
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.